Free Daily Headlines :

  • COVID-19
  • Vaccine Info
  • Money
  • Politics
  • Education
  • Health
  • Justice
  • More
    • Environment
    • Economic Development
    • Gaming
    • Investigations
    • Social Services
    • TRANSPORTATION
  • Opinion
    • CT Viewpoints
    • CT Artpoints
DONATE
Reflecting Connecticut’s Reality.
    COVID-19
    Vaccine Info
    Money
    Politics
    Education
    Health
    Justice
    More
    Environment
    Economic Development
    Gaming
    Investigations
    Social Services
    TRANSPORTATION
    Opinion
    CT Viewpoints
    CT Artpoints

LET�S GET SOCIAL

Show your love for great stories and out standing journalism

Connecticut leads 20 states alleging price-fixing in generic drugs

  • Health
  • by Mark Pazniokas
  • December 15, 2016
  • View as "Clean Read" "Exit Clean Read"
Attorney General George Jepsen

Attorney General George Jepsen

Attorney General George Jepsen’s office is leading a multi-state investigation of generic drug companies that culminated Thursday in a federal price-fixing lawsuit filed in Hartford that complements an unfolding criminal antitrust investigation by the U.S. Department of Justice.

The lawsuit follows an extensive investigation involving 20 states and was filed after federal authorities unsealed charging documents in Pennsylvania that allege a price-fixing conspiracy by two former executives of Heritage Pharmaceuticals and unnamed co-conspirators.

Heritage was one of six pharmaceutical companies named as defendants in the Connecticut lawsuit, filed under seal to protect what Jepsen says is a continuing investigation. A redacted version was made public Thursday by Jepsen’s office.

“My office has dedicated significant resources to this investigation for more than two years and has developed compelling evidence of collusion and anticompetitive conduct across many companies that manufacture and market generic drugs in the United States,” Jepsen said. “While the principal architect of the conspiracies addressed in this lawsuit was Heritage Pharmaceuticals, we have evidence of widespread participation in illegal conspiracies across the generic drug industry.”

READ THE LAWSUIT

The lawsuit alleges that industry officials conspired at trade shows, golf outings, private dinners and by text message and cell phone calls. Female sales representatives traded pricing informing at what they euphemistically called “girls night out” or “Women in Industry” dinners.

Jepsen’s office says it began investigating after prices of generics skyrocketed throughout 2013 and into 2014. Prices of more than 1,200 medications increased an average of 448 percent from July 2013 to July 2014, when the investigation began, according to the lawsuit.

“Ultimately, it was consumers – and, indeed, our healthcare system as a whole – who paid for these actions through artificially high prices for generic drugs,” Jepsen said. “We intend to pursue this and other enforcement actions aggressively, and look forward to working with our colleagues across the country to restore competition and integrity to this important market.”

The lawsuit focuses on an antibiotic, doxycycline hyclate delayed release, and glyburide, an oral diabetes medication. But the investigation is broader, Jepsen’s office says.

Doxycycline was one of the drugs cited by U.S. Sen. Bernie Sanders, I-Vt., and U.S. Rep. Elijah E. Cummings, D-Md., as they announced a congressional investigation two months ago into generics. They said the antibiotic, prescribed for Lyme disease, cost $20 for a bottle of 500 tablets in October 2015, then jumped by April to $1,849.

Jepsen’s suit says the companies violated the federal Sherman Act and asks the court to enjoin them from engaging in illegal, anticompetitive behavior. It seeks unspecified damages, including the seizure of illegal profits.

The pharmaceutical companies are accused of fixing prices by manipulating markets – companies would agree not to compete on certain drugs – or simply agreeing on how high to raise prices.

Joining Connecticut in the lawsuit are Delaware, Florida, Hawaii, Idaho, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Minnesota, Nevada, New York, North Dakota, Ohio, Pennsylvania, Virginia and Washington.

Named as defendants are Heritage Pharmaceuticals, Inc., Aurobindo Pharma USA, Inc., Citron Pharma, LLC, Mayne Pharma (USA), Inc., Mylan Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc.

“The principal architect and ringleader of the conspiracies identified herein is Defendant Heritage,” the suit says. “Through its senior-most executives and salespersons, Heritage organized and initiated a wide-ranging series of conspiracies which included numerous generic drug manufacturers, all of whom were knowing and willing participants. Collectively, Defendants were able to obtain a substantial windfall as a result of these illegal agreements.”

Bloomberg news disclosed the existence of the criminal investigation a month ago.

In the charges made public Wednesday, the Justice Department alleged that Jeffrey Glazer and Jason Malek, then senior Heritage executives, conspired to fix prices on the same two drugs involved in Jepsen’s lawsuit.

Heritage offered little additional comment Thursday beyond the statement it made about the criminal investigation:

“In August 2016, following an internal investigation that revealed a variety of serious misconduct by the individuals charged today, Heritage Pharmaceuticals terminated them. We are fully cooperating with all aspects of the Department of Justice’s continuing investigation. Recently Heritage initiated its own legal action against these same individuals to seek redress for an elaborate embezzlement and self-dealing scheme. We are deeply disappointed by the misconduct and are committed to ensuring it does not happen again.”

Denise Bradley, a senior vice president of Teva, said, “We have not found evidence that would give rise to any civil or criminal liability.”

Mylan’s chief executive officer, Heather Bresch, was called before Congress this year to defend her company’s steep increases in the price of its EpiPen, an injector used by individuals with life-threatening allergies. The EpiPen is not an element of the lawsuit filed Thursday.

After her testimony, the New York Times described Bresch, the daughter of U.S. Sen. Joe Manchin, D-West Va., as America’s “new pharmaceutical villain.”

In a statement Thursday about Jepsen’s lawsuit, the company said, “To date, we know of no evidence that Mylan participated in price fixing.”

Sign up for CT Mirror's free daily news summary.

Free to Read. Not Free to Produce.

The Connecticut Mirror is a nonprofit newsroom. 90% of our revenue comes from people like you. If you value our reporting please consider making a donation. You'll enjoy reading CT Mirror even more knowing you helped make it happen.

YES, I'LL DONATE TODAY

ABOUT THE AUTHOR

Mark Pazniokas is the Capitol Bureau Chief and a co-founder of CT Mirror. He is a frequent contributor to WNPR, a former state politics writer for The Hartford Courant and Journal Inquirer, and contributor for The New York Times.

SEE WHAT READERS SAID

RELATED STORIES
CT lawmakers call for funding to stop ‘mass killing’ of Black and brown children
by Kelan Lyons

Lawmakers identified a $5 billion proposal by the Biden administration, and marijuana and sports-betting legalization efforts, as potential funding.

CT’s prison population shrunk during the pandemic. Will it last?
by Kelan Lyons and Kasturi Pananjady

The historic declines coincide with a demand for equity as racial disparities in the incarcerated populate have widened during COVID-19.

Can independent primary care doctors survive dominance of hospital health systems?
by Peggy McCarthy | C-HIT.ORG

hospital systems and private businesses are increasingly buying private medical practices and taking over their business operations.

Keep youths out of the justice system, or hold them accountable? Judiciary committee advances bills that do both
by Kelan Lyons

Republicans were concerned about a provision in one bill that would erase certain juvenile records.

DCF commissioner says old juvenile detention center could humanely shelter migrant kids
by Mark Pazniokas and Kelan Lyons

Officials say a closed juvenile detention center's history should not rule out repurposing it as a shelter for migrant children.

Support Our Work

Show your love for great stories and outstanding journalism.

$
Select One
  • Monthly
  • Yearly
  • Once
Artpoint painter
CT ViewpointsCT Artpoints
Opinion A healthcare system too broken to fix
by Sosena Kedebe MD

On March 25, the White house announced that it was going to invest over $6 billion in health centers that are funded through the Resources and Services Administration (HRSA) in order to expand COVID-19 vaccinations and other health services provided to vulnerable populations. As a chief medical officer for a health center that is strained to reach some of the most disenfranchised patient population in Hartford, this was great news. Yet there was a part of me that took the news with a deep concern. Why you might ask?

Opinion The Connecticut Juvenile Training School and the lie that built it
by Colleen Shaddox 

Sitting in the paddy wagon, I was afraid – maybe apprehensive was a better word, since I rightly suspected that white privilege would guarantee me good treatment.  Still, I said a prayer of thanksgiving. After years of advocating for people in our carceral system, I was given a chance to develop more empathy.

Opinion Data on race, ethnicity and language is critical to making real healthcare progress
by Vicki Veltri, Tekisha Everette and Matt McDermott.

There are significant disparities in health status based upon race, ethnicity, and other factors that deprive many Connecticut residents of an equal opportunity to enjoy good health and well-being. That some Connecticut residents live without proper treatment of illness and injury due to disparities in health care access, affordability, and outcomes based upon race, ethnicity, and language (REL) is self-evident to many but not to all.

Opinion SB 1018: Connecticut’s effort to increase prosecutorial accountability and why it will not work
by Olivia Louthen

Senate Bill 1018 does not solve Connecticut’s largest criminal justice problem: outcomes for crime victims and defendants vary based on zip codes because judicial districts operate independently of one another.

Artwork Grand guidance
by Anne:Gogh

In a world of systemic oppression aimed towards those of darker skintones – representation matters. We are more than our equity elusive environments, more than numbers in a prison and much more than victims of societal dispositions. This piece depicts a melanated young man draped in a cape ascending high above multiple forms of oppression. […]

Artwork Shea
by Anthony Valentine

Shea is a story about race and social inequalities that plague America. It is a narrative that prompts the question, “Do you know what it’s like to wake up in new skin?”

Artwork The Declaration of Human Rights
by Andres Chaparro

Through my artwork I strive to create an example of ideas that reflect my desire to raise social consciousness, and cultural awareness. Jazz music is the catalyst to all my work, and plays a major influence in each piece of work.”

Artwork ‘A thing of beauty. Destroy it forever’
by Richard DiCarlo | Derby

During times like these it’s often fun to revisit something familiar and approach things with a different slant. I have been taking some Pop culture and Art masterpieces and applying the vintage 1960’s and 70’s classic figures (Fisher Price, little people) to the make an amusing pieces. Here is my homage to Fisher -Price, Yellow […]

Twitter Feed
A Twitter List by CTMirror

Engage

  • Reflections Tickets & Sponsorships
  • Events
  • Donate
  • Newsletter Sign-Up
  • Submit to Viewpoints
  • Submit to ArtPoints
  • Economic Indicator Dashboard
  • Speaking Engagements
  • Commenting Guidelines
  • Legal Notices
  • Contact Us

About

  • About CT Mirror
  • Announcements
  • Board
  • Staff
  • Sponsors and Funders
  • Donors
  • Friends of CT Mirror
  • History
  • Financial
  • Policies
  • Strategic Plan

Opportunity

  • Advertising and Sponsorship
  • Speaking Engagements
  • Use of Photography
  • Work for Us

Go Deeper

  • Steady Habits Podcast
  • Economic Indicator Dashboard
  • Five Things

The Connecticut News Project, Inc. 1049 Asylum Avenue, Hartford, CT 06105. Phone: 860-218-6380

© Copyright 2021, The Connecticut News Project. All Rights Reserved. Website by Web Publisher PRO